Entact Bio CEO Victoria Richon
December 6, 2022 07:00 AM ESTUpdated 07:41 AM
Financing
Startups

En­tact Bio makes its Se­ries A de­but with $81M to launch pro­tein en­hance­ment plat­form

Katherine Lewin

News Reporter

En­tact Bio has se­cured $81 mil­lion in a Se­ries A round to push for­ward its plat­form for de­vel­op­ing ther­a­pies that can en­hance the func­tion of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times